drugset / Trial / NCT07571824

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

NCT07571824

Phase 1 Completed 92 enrolled Corium Innovations, Inc.
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this research study is to compare the bioavailability and adhesion of a generic Selegiline transdermal system (TDS) against the marketed comparator (EMSAM®) in healthy volunteers. Systemic and local safety and tolerability will be also observed and evaluated.

Timeline

Start
2026-03-23
Primary completion
2026-06-16
Completion
2026-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Selegiline Unknown 6 mg Other

Indications

No indication recorded.